Autres langues Dimerix Limited

Actions

DXB

AU000000DXB7

Marché Fermé - Australian S.E. Autres places de cotation 08:10:52 24/04/2024			Varia. 5j.	Varia. 1 janv.
0,335 ^AUD	+9,84 %		+17,54 %	+63,41 %

19/04	DIMERIX LIMITED : Euroz Hartleys maintient sa recommandation à l'achat	ZM
12/03	Dimerix lève 20 millions de dollars australiens pour une étude sur les maladies rénales	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	22/04
Dimerix Raises AU$20 Million for Kidney Disease Study	12/03
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo	11/03
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023	25/02
Dimerix Limited Announces Appointment of Mark Diamond as Director	01/12
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%	28/11
Dimerix Appoints Nonexecutive Chair	20/11
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights	07/11
Dimerix Appoints Medical Chief	23/10/23
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer	22/10/23
ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand	05/10/23
Softer US Employment Data End Australian Shares' Three-Day Losing Streak	05/10/23
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug	05/10/23
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name	25/09/23
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia	22/09/23
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%	13/09/23
Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe	05/07/23
Dimerix Secures Study Design Approval in China for Phase Three Kidney Disease Trial; Shares Rise 6%	03/07/23
Dimerix Raising AU$12 Million to Continue Clinical Program; Shares Down 7%	04/05/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Dimerix Limited

Actions

DXB

AU000000DXB7

Autres langues

Filtres